Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Bausch Health Companies Inc (BHC)

Bausch Health Companies Inc (BHC)
6.36 +0.20 (+3.25%) 02/18/25 [NYSE]
6.40 x 4 6.57 x 3
Realtime by (Cboe BZX)
6.40 x 4 6.57 x 3
Realtime 6.41 +0.05 (+0.79%) 17:42 ET
Quote Overview for Tue, Feb 18th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
6.13
Day High
6.39
Open 6.19
Previous Close 6.16 6.16
Volume 7,594,580 7,594,580
Avg Vol 4,265,275 4,265,275
Stochastic %K 6.65% 6.65%
Weighted Alpha -34.94 -34.94
5-Day Change +0.04 (+0.63%) +0.04 (+0.63%)
52-Week Range 3.96 - 11.46 3.96 - 11.46
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,227,820
  • Shares Outstanding, K 361,659
  • Annual Sales, $ 8,757 M
  • Annual Income, $ -592,000 K
  • EBIT $ 2,547 M
  • EBITDA $ 3,876 M
  • 60-Month Beta 0.68
  • Price/Sales 0.24
  • Price/Cash Flow 0.88
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 79.51% ( +11.31%)
  • Historical Volatility 43.72%
  • IV Percentile 83%
  • IV Rank 30.12%
  • IV High 177.43% on 07/24/24
  • IV Low 37.30% on 05/24/24
  • Put/Call Vol Ratio 0.30
  • Today's Volume 1,912
  • Volume Avg (30-Day) 4,305
  • Put/Call OI Ratio 4.16
  • Today's Open Interest 172,761
  • Open Int (30-Day) 155,606

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.12
  • Number of Estimates 6
  • High Estimate 1.37
  • Low Estimate 0.90
  • Prior Year 1.15
  • Growth Rate Est. (year over year) -2.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.12 +3.92%
on 02/14/25
Period Open: 7.44
8.02 -20.70%
on 01/24/25
-1.08 (-14.52%)
since 01/17/25
3-Month
6.12 +3.92%
on 02/14/25
Period Open: 8.38
8.52 -25.31%
on 12/10/24
-2.02 (-24.11%)
since 11/18/24
52-Week
3.96 +60.61%
on 07/24/24
Period Open: 8.51
11.46 -44.50%
on 04/03/24
-2.15 (-25.26%)
since 02/16/24

Most Recent Stories

More News
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference

LAVAL, QC / ACCESS Newswire / February 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that it will participate in the 2025 J.P. Morgan Global Leveraged Finance Conference...

BHC.TO : 9.03 (+3.44%)
BHC : 6.36 (+3.25%)
Bausch Health Announces 2025 Salix Gastrointestinal Health Scholars Program

Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases

BHC.TO : 9.03 (+3.44%)
BHC : 6.36 (+3.25%)
Bausch Health Provides Update on Strategic Alternatives

LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through...

BLCO.TO : 23.09 (-1.45%)
BHC.TO : 9.03 (+3.44%)
BLCO : 16.35 (-0.37%)
BHC : 6.36 (+3.25%)
Bausch Health to Announce Fourth Quarter and Full Year 2024 Results on February 19, 2025

LAVAL, QC / ACCESS Newswire / January 23, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release fourth quarter and full year 2024 financial results after market close on Wednesday, February...

BHC.TO : 9.03 (+3.44%)
BHC : 6.36 (+3.25%)
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act's Medicare Negotiation Program

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for...

BHC.TO : 9.03 (+3.44%)
BHC : 6.36 (+3.25%)
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a...

BHC.TO : 9.03 (+3.44%)
BHC : 6.36 (+3.25%)
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation...

BHC.TO : 9.03 (+3.44%)
BHC : 6.36 (+3.25%)
Bausch Health Appoints New Chief Medical Officer and Head of R&D

LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical...

BHC.TO : 9.03 (+3.44%)
BHC : 6.36 (+3.25%)
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis

Next generation product may increase gastrointestinal luminal concentration while limiting system exposure

BHC.TO : 9.03 (+3.44%)
BHC : 6.36 (+3.25%)
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health...

BHC.TO : 9.03 (+3.44%)
BHC : 6.36 (+3.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic...

See More

Key Turning Points

3rd Resistance Point 6.72
2nd Resistance Point 6.55
1st Resistance Point 6.46
Last Price 6.36
1st Support Level 6.20
2nd Support Level 6.03
3rd Support Level 5.94

See More

52-Week High 11.46
Fibonacci 61.8% 8.59
Fibonacci 50% 7.71
Fibonacci 38.2% 6.82
Last Price 6.36
52-Week Low 3.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion